

Resource Summary Report

Generated by [Kravitz](#) on Sep 10, 2026

ADTE_x

RRID:SCR_012059

Type: Tool

Proper Citation

ADTE_x (RRID:SCR_012059)

Resource Information

URL: <http://sourceforge.net/projects/adtex/>

Proper Citation: ADTE_x (RRID:SCR_012059)

Description: A software tool for copy number variation (CNV) detection for whole-exome data from paired tumour/matched normal samples.

Resource Type: software resource

Defining Citation: [PMID:23368785](#)

Keywords: standalone software, python, r

Availability: GNU General Public License

Resource Name: ADTE_x

Resource ID: SCR_012059

Alternate IDs: OMICS_03365

Record Creation Time: 20220129T080308+0000

Record Last Update: 20260905T132720+0000

Ratings and Alerts

No rating or validation information has been found for ADTE_x.

No alerts have been found for ADTE_x.

Data and Source Information

Usage and Citation Metrics

We found 95 mentions in open access literature.

Listed below are recent publications. The full list is available at [Kravitz](#) .

Feng J, et al. (2026) Molecular and clinical characteristics of glioma patients with germline pathogenic mutations of Lynch syndrome genes: a large-scale multicenter study. *Journal of translational medicine*, 24(1).

Zhang Y, et al. (2026) Gene mutation in metabolism syndrome with hematologic tumor: A retrospective cohort study. *Clinical and experimental medicine*, 26(1), 126.

Liang JH, et al. (2026) Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution. *BMC medicine*, 24(1).

Lin Y, et al. (2026) Identification of a distinct epigenetic subgroup with inferior PFS in intracranial mesenchymal tumors with FET::CREB fusion. *Brain pathology (Zurich, Switzerland)*, 36(2), e70040.

Hang JF, et al. (2026) Out-of-frame CBX3::ALK fusion drives ALK activation and therapy response. *Cell reports. Medicine*, 7(4), 102697.

Zhu J, et al. (2025) Genomic profiles and prognostic biomarkers of resectable lung adenocarcinoma with a micropapillary component. *Frontiers in oncology*, 15, 1574817.

Lei Y, et al. (2025) Molecular features influencing clinical outcome of advanced HER2-positive gastric cancer receiving trastuzumab plus chemotherapy. *Annals of medicine*, 57(1), 2581815.

Zhang L, et al. (2025) High-grade uterine endometrial stromal sarcoma harboring GLI1 and MDM2/CDK4 co-amplifications. *Diagnostic pathology*, 20(1), 125.

Wang Z, et al. (2025) Role of telomere maintenance genes as a predictive biomarker for colorectal cancer immunotherapy response and prognosis. *Biomolecules & biomedicine*, 25(12), 2696.

Gao Y, et al. (2025) High-Dose Methotrexate, Ibrutinib, and Temozolomide in the Treatment of Newly Diagnosed Primary CNS Lymphoma: A Multicenter, Prospective Phase II Study. *Blood cancer discovery*, 6(3), 191.

Liu H, et al. (2025) Plasma-Based Genomic Features Influencing Outcomes of T790M-Positive Non-Small Cell Lung Cancer Receiving Osimertinib. *Cancer medicine*, 14(21), e71319.

Yang L, et al. (2025) Gene mutation in cancer patients with diabetes: a real-world retrospective cohort study. *BMC cancer*, 25(1), 1163.

Sun M, et al. (2025) Two similar but distinct types of breast acinar cell carcinoma: evidence from histological, immunohistochemical and molecular features. *Histopathology*, 87(6), 904.

Hu J, et al. (2025) MET and NF2 alterations confer primary and early resistance to first-line alectinib treatment in ALK-positive non-small-cell lung cancer. *Molecular oncology*, 19(9), 2715.

Wu L, et al. (2025) Integration of Circulating Tumor DNA and Metabolic Parameters on 18F-Fludeoxyglucose Positron Emission Tomography for Outcome Prediction in Unresectable Locally Advanced Non-Small Cell Lung Cancer. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 12(13), e2413125.

Zhang H, et al. (2025) Genomic mutation profile and metabolic alterations in diffuse large B-cell lymphoma with abdominal bulky mass. *Annals of hematology*, 104(6), 3359.

Jiang M, et al. (2024) Patient-derived organoids and mini-PDX for predicting METN375S-mutated lung cancer patient clinical therapeutic response. *Heliyon*, 10(18), e37884.

Ding X, et al. (2024) Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer. *Cell communication and signaling : CCS*, 22(1), 45.

Chen C, et al. (2024) Plasma circulating tumour DNA is a better source for diagnosis and mutational analysis of IVLBCL than tissue DNA. *Journal of cellular and molecular medicine*, 28(14), e18576.

Zhang Y, et al. (2024) Toripalimab plus anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm phase 2 trial (TORAL). *Cell reports. Medicine*, 5(12), 101833.